How This Actually Works, Step by Step

Michael’s journey started with a pile of medical records, not a plane ticket. That’s the right order. Here’s the sequence we walk every international patient through.

First, you send us what you have: pathology reports, imaging (CT/MRI/PET scans on CD or via secure upload), surgical notes if applicable, current medication list, and a one-page summary of your diagnosis and treatment history. Our medical translation team renders it into clinical Chinese — not conversational Chinese, but the precise terminology a Chinese oncology department expects to see. That step alone takes 2–4 business days.

We then route your file to the appropriate department at hospitals within our network of 340+ top-ranked hospitals. For colorectal cancer, that might mean the GI oncology division at Zhongshan Hospital Fudan University or the cancer center at Peking Union Medical College Hospital. A senior specialist reviews your records and returns either a written second opinion ($300–500) or joins a video consultation ($500–800 for a top specialist) where you discuss treatment options directly.

If the recommendation is surgery or a specific treatment protocol requiring you to travel, we coordinate the S2 visa documentation, hospital appointment scheduling through the international department, and on-ground support. You don’t fly to China hoping for a consultation. You fly with a confirmed appointment and a treatment plan already under review.

What “Evidence-Based” Actually Means at Chinese Oncology Centers

China’s top cancer hospitals publish in the same journals as MD Anderson and Memorial Sloan Kettering. Fudan University’s Shanghai Cancer Center contributed patient data to multiple international phase III trials. The Chinese Society of Clinical Oncology (CSCO) issues annual guidelines that mirror NCCN recommendations with some regional modifications based on local epidemiology — for example, higher proportions of EGFR-mutant lung cancer in Asian populations, which changes first-line therapy choices.

This isn’t alternative medicine. It’s protocol-driven oncology. A patient with HER2-positive breast cancer at Ruijin Hospital in Shanghai will receive trastuzumab-based therapy because the HERA trial proved it works. A patient with EGFR-mutant non-small cell lung cancer will be offered osimertinib because the FLAURA trial showed superior progression-free survival. The evidence base is identical. The delivery system is different.

What’s different is volume. Chinese top-tier surgical oncologists operate at case volumes that Western surgeons rarely see. Fuwai Hospital performs over 14,000 cardiac surgeries annually — that’s a cardiovascular example, but the same volume pattern holds in surgical oncology. A thoracic surgeon at a major Chinese cancer center may perform 300–500 lung cancer resections per year. Volume correlates with outcomes in complex surgery. That’s not anecdote; that’s the volume-outcome relationship documented in surgical literature for decades.

So when patients ask whether Chinese cancer care is evidence-based, the honest answer is: at the top hospitals, yes — and the evidence is applied at higher volume than most Western centers can match.

A Realistic Timeline

People underestimate the administrative runway. Here’s what a typical international cancer patient actually experiences, from first contact to treatment start.

That’s roughly 10–12 weeks from first email to treatment start. Some patients move faster — a video consultation can compress the early stages. Others move slower if their consulate has a backlog or if the hospital requests additional imaging. The S2 visa step is the one patients consistently underestimate. You need a hospital-issued invitation letter and supporting medical documents. We provide the template and guidance, but the consulate controls the timeline.

What Can Go Wrong — and What Happens Then

Let’s be direct about failure modes, because pretending they don’t exist helps no one.

Your records are incomplete or low-quality. A Chinese specialist cannot assess what they cannot see. If your CT scan is a blurry fax or your pathology report lacks immunohistochemistry staining results, the review stalls. What happens: we tell you exactly which documents are missing and help you request them from your home hospital. This adds 1–3 weeks.

The specialist recommends against travel. Sometimes the honest medical opinion is that your case is better managed at home — for example, if you need urgent treatment and cannot afford a 10-week runway, or if your cancer type is one where Chinese outcomes don’t differ meaningfully from your local center. What happens: you’ve paid for a second opinion, not a travel package. You keep the written analysis and treatment recommendations. That’s the point of the staged model.

Your visa is delayed or denied. S2 visas are generally straightforward for documented medical travel, but consulates can request additional proof of funds, return intent, or hospital confirmation. What happens: we extend the hospital appointment and resubmit documentation. We cannot guarantee approval — no legitimate service can — but a complete application with a hospital letter resolves most delays.

The hospital changes your treatment plan after in-person evaluation. This happens. A remote review of scans is not the same as an in-person examination with fresh imaging. The Chinese team may upgrade your staging, order additional tests, or adjust the protocol. What happens: you’re now in the hands of the treating team. The remote opinion was a bridge, not a binding contract. Most patients find the adjusted plan is more precise, not less.

Is Immunotherapy Available in China — and How Does It Compare to the US?

Yes. China has approved multiple PD-1 and PD-L1 inhibitors, including domestic agents like toripalimab, sintilimab, camrelizumab, and tislelizumab, alongside international drugs like pembrolizumab and nivolumab. The domestic PD-1 inhibitors are a major reason China’s oncology costs run lower than the US — Chinese-developed checkpoint inhibitors are priced at a fraction of Keytruda or Opdivo, with published phase III data in multiple cancer types.

But here’s the nuance patients need. How does China cancer treatment compare to US care in immunotherapy? In terms of drug availability, China’s approved PD-1 list is broad but not identical to the FDA’s. Some newer combination approvals arrive in China 12–24 months later. In terms of cost, the gap is stark: a year of domestic PD-1 therapy in China can run $8,000–15,000 versus $150,000+ for branded checkpoint inhibitors in the US. In terms of clinical expertise, the top cancer centers in Shanghai and Beijing have deep experience managing immune-related adverse events, which is where real-world outcomes are won or lost.

One more consideration: clinical trials. China has become a global hub for oncology trials, particularly for domestic PD-1 agents and CAR-T therapies. International patients sometimes ask about clinical trials cancer China international patients can access. The honest answer: most Chinese clinical trials enroll domestic patients, and international enrollment is handled case-by-case. Some trials accept foreign participants if they meet inclusion criteria and can attend all required visits. If a trial is relevant to your cancer type, we can inquire — but we don’t promise trial access. That would be irresponsible.

Choosing a Hospital: What the Rankings Actually Measure

Patients searching for the best cancer hospital Shanghai for foreigners often assume there’s a single answer. There isn’t. The Fudan University hospital rankings — China’s most authoritative — evaluate hospitals on clinical reputation and research output. The oncology specialty list ranks departments, not whole hospitals. A hospital might be excellent in lung cancer but average in gynecologic oncology.

For international patients, three factors matter more than rank: does the hospital have a dedicated international medical department with English-speaking coordinators? Does it accept foreign patients through a structured pathway rather than ad hoc arrangements? Does it have experience with your specific cancer type at high volume?

Shanghai’s top options for international oncology patients include Zhongshan Hospital Fudan University (strong in GI and liver cancers), Ruijin Hospital (hematologic malignancies, breast cancer), and Fudan University Shanghai Cancer Center (comprehensive oncology, high trial volume). Beijing offers Peking Union Medical College Hospital (complex cases, multidisciplinary approach) and Cancer Hospital Chinese Academy of Medical Sciences (China’s national cancer center). Each has an international department. Each handles foreign patients regularly. The right choice depends on your specific diagnosis, not a generic “best hospital” list.

If you’re evaluating options, our Shanghai hospital guide breaks down the city’s top-ranked institutions by specialty. And for patients who want a broader view, the oncology specialty rankings show which departments lead in your cancer type.

Practical Considerations: Records, Visa, Payment, and Follow-Up

Records come first. Always. A complete clinical dossier — pathology, imaging, surgical notes, treatment history, medication list — is the single biggest determinant of whether a Chinese oncology team can give you a meaningful opinion. Gaps in records cause delays and weaken the review quality.

Visa category is S2 for medical treatment under 180 days. Your accompanying family member also applies for an S2. The hospital’s international department issues an invitation letter that supports your application. Start this process early — consulate processing times range from a few days to several weeks depending on your home country.

Payment at Chinese public hospitals is prepaid. You’ll deposit funds at admission and settle on discharge. Insurance is typically reimbursement-based: you pay upfront, then claim from your insurer. Private international hospitals in China, like United Family or Jiahui, offer direct insurance billing if your policy covers them — but their oncology capabilities are generally narrower than the top public academic centers.

Language is the friction point nobody anticipates until they’re standing in a Chinese hospital corridor at 7 a.m. with 10,000 other patients. Signage is increasingly bilingual, but the actual clinical conversations happen in Chinese. A bilingual medical companion — from $300 per day — handles registration, queue management, payment, and interpretation. It’s not a luxury. For most international patients, it’s the difference between a manageable experience and a disorienting one.

Follow-up after returning home: Chinese oncologists will provide a written treatment summary and recommended follow-up schedule in English. Your home oncologist can then take over monitoring. Some patients return to China for periodic imaging or continued therapy; others transfer care entirely. Both are workable.

Frequently Asked Questions